Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.

Zepbound was approved last year to treat obesity. The drug's maker, Eli Lilly, says it reduces the severity of obstructive sleep apnea by 63%.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Some individuals living with obesity and overweight may find it difficult to embark on a weight loss journey alone. It’s not ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Last week, Australia's Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnea, a condition in which breathing stops and starts repeatedly during sleep.